*ion*torrent

Test to treat more NSCLC patients



Clinical practice guidelines recommend broad genetic profiling for advanced non-small cell lung cancer (NSCLC) to guide first-line treatment.



Small biopsies and low-tumor content samples pose challenges to testing of an increasing number of relevant biomarkers.



Next-generation sequencing (NGS) can help address these challenges, but not all NGS is the same.

NSCLC tissue samples are small and challenging to test.



1,324 routine clinical NSCLC samples were tested by single-gene methods. The majority of these samples were CNBs, of which 21% had tumor content below 25%.

Tissue requirements rise and success rates fall

as more results are performed with single-gene methods. The lon Torrent[™] Oncomine[™] Dx Target Test achieves **71% success with only 1 tissue slide.**



As more genes are required, slide consumption when using single-gene methods continues to increase (in some cases requiring 19 slides), but the success rate continues to fall. The sample used for the Oncomine Dx Target Test was restricted to only one slide for this study.



When requirement of number of genes increased, success rate tends to decline. When 4 genes are required, only 71% of patients received results. Testing success rates for the Oncomine Dx Target Test using just one slide were comparable to single-gene testing for \geq 4 biomarkers on low-tumor content CNBs and \geq 5 biomarkers on CNBs with \geq 25% tumor content

The figures used above are based on: Yu T, Morrison C, Gold E et al. (2017). Retrospective Analysis of NSCLC Testing in Low Turnor Content Samples: Single-Gene Tests, NGS, & the Oncomine™ Dx Target Test. J Thorac Oncol 12:S1845.

Not every NGS test has the same low sample requirements. Comparison of two FDA-approved companion diagnostic (CDx) tests:



The figures used above are based on published sample requirements for both tests. The Oncomine Dx Target Test is approved for use with formalin-fixed, paraffin-embedded (FFPE) tissue from NSCLC surgical resections and CNBs.

Test to treat more patients with the Oncomine Dx Target Test





Because the Oncomine Dx Target Test has low sample requirements, you can test to enable treatment of more NSCLC patients.

Find out more at thermofisher.com/oncomine-dxtarget

For *In Vitro* Diagnostic Use. © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. FoundationOne CDx is a trademark of FOUNDATION MEDICINE, INC. COL06082 0418

Thermo Fisher

*ion*torrent

Test to treat more NSCLC patients



Clinical practice guidelines recommend broad genetic profiling for advanced non-small cell lung cancer (NSCLC) to guide first-line treatment.



Small biopsies and low-tumor content samples pose challenges to testing of an increasing number of relevant biomarkers.



Next-generation sequencing (NGS) can help address these challenges.

NSCLC tissue samples are small and challenging to test.



1,324 routine clinical NSCLC samples were tested by single-gene methods. The majority of these samples were CNBs, of which 21% had tumor content below 25%.

Tissue requirements rise and success rates fall

as more results are performed with single-gene methods. The lon Torrent[™] Oncomine[™] Dx Target Test achieves **71% success with only 1 tissue slide.**



As more genes are required, slide consumption when using single-gene methods continues to increase (in some cases requiring 19 slides), but the success rate continues to fall. The sample used for the Oncomine Dx Target Test was restricted to only one slide for this study.

	95%	88%					
ouccess rate			70%	71%	62%	60%	
	1	2	3 Nu	4 umber of g	5 jenes	6	23

When requirement of number of genes increased, success rate tends to decline. When 4 genes are required, only 71% of patients received results. Testing success rates for the Oncomine Dx Target Test using just one slide were comparable to single-gene testing for ≥4 biomarkers on low-tumor content CNBs and ≥5 biomarkers on CNBs with ≥25% tumor content.

The figures used above are based on: Yu T, Morrison C, Gold E et al. (2017). Retrospective Analysis of NSCLC Testing in Low Tumor Content Samples: Single-Gene Tests, NGS, & the Oncomine™ Dx Target Test. J Thorac Oncol 12:S1845.

Test to treat more patients with the Oncomine Dx Target Test



Because the Oncomine Dx Target Test has low sample requirements, you can test to enable treatment of more NSCLC patients.

Find out more at thermofisher.com/oncomine-dxtarget

For In Vitro Diagnostic Use. © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. FoundationOne CDx is a trademark of FOUNDATION MEDICINE, INC. COL06082 0418



*ion*torrent

Test to treat more NSCLC patients



Clinical practice guidelines recommend broad genetic profiling for advanced non-small cell lung cancer (NSCLC) to guide first-line treatment.



Small biopsies and low-tumor content samples pose challenges to testing of an increasing number of relevant biomarkers.



Next-generation sequencing (NGS) can help address these challenges by detecting more biomarkers in one test, however, not all NGS requires the same small amount of sample.

Not every NGS test has the same low sample requirements. Comparison of two FDA-approved companion diagnostic (CDx) tests:



The figures used above are based on published sample requirements for both tests. The Oncomine Dx Target Test is approved for use with formalin-fixed, paraffin-embedded (FFPE) tissue from NSCLC surgical resections and CNBs.

Test to treat more patients with

the Oncomine Dx Target Test



Because the Oncomine Dx Target Test has low sample requirements, you can test to enable treatment of more NSCLC patients.

Find out more at thermofisher.com/oncomine-dxtarget

For *In Vitro* Diagnostic Use. © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. FoundationOne CDx is a trademark of FOUNDATION MEDICINE, INC. COL06082 0418

